VOLUME 63   2002   NUMBER 3

CME Pretest 178

CME Posttest 255

Brainstorms

179 Selective Actions on Sleep or Anxiety by Exploiting GABA-A/Benzodiazepine Receptor Subtypes. Stephen M. Stahl
[PDF]

Original Articles

181 Combining Bupropion SR With Venlafaxine, Paroxetine, or Fluoxetine: A Preliminary Report on Pharmacokinetic, Therapeutic, and Sexual Dysfunction Effects. Sidney H. Kennedy, Sonia M. McCann, Mario Masellis, Roger S. McIntyre, Joel Raskin, Gordon McKay, and Glen B. Baker
[Abstract] [PDF]

187 Major Depressive Disorder and Axis I Diagnostic Comorbidity. [CME] Mark Zimmerman, Iwona Chelminski, and Wilson McDermut
[Abstract] [PDF]

194 An Open-Label Trial of Citalopram for Major Depression in Patients With Hepatitis C. Ondria C. Gleason, William R. Yates, M. Daniel Isbell, and Michelle A. Philipsen
[Abstract] [PDF]

199 Fluoxetine Versus Placebo in Posttraumatic Stress Disorder. Ferenc Martenyi, Eileen B. Brown, Harry Zhang, Apurva Prakash, and Stephanie C. Koke
[Abstract] [PDF]

207 Correlates of Overweight and Obesity in 644 Patients With Bipolar Disorder. Susan L. McElroy, Mark A. Frye, Trisha Suppes, Dawn Dhavale, Paul E. Keck, Gabriele S. Leverich, Lori Altshuler, Kirk D. Denicoff, Willem A. Nolen, Ralph Kupka, Heinz Grunze, Jrg Walden, and Robert M. Post
[Abstract] [PDF]

214 Normal P50 Gating in Children With Autism. [CME] Chantal Kemner, Bob Oranje, Marinus N. Verbaten, and Herman van Engeland
[Abstract] [PDF]

218 Carbamazepine Augmentation for Schizophrenia: How Good Is the Evidence? Stefan Leucht, John McGrath, Paul White, and Werner Kissling
[Abstract] [PDF]

225 Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial. David J. Goldstein, Craig Mallinckrodt, Yili Lu, and Mark A. Demitrack
[Abstract] [PDF]

232 Switching Patients From Daily Citalopram, Paroxetine, or Sertraline to Once-Weekly Fluoxetine in the Maintenance of Response for Depression. Cherri M. Miner, Eileen B. Brown, Jill S. Gonzales, and Reema Munir
[Abstract] [PDF]

241 Treatment of Borderline Personality Disorder With Risperidone. Paola Rocca, Livio Marchiaro, Elena Cocuzza, and Filippo Bogetto
[Abstract] [PDF]

Academic Highlights

259 Understanding Changes in Cholinergic Function: Implications for Treating Dementia.
[PDF]

Letters To the Editor

245 Mechanisms of Weight Gain Induced by Antipsychotic Drugs. Trino Baptista
[PDF]

246 Eosinophilia Associated With Olanzapine. Stefan Mathias, Ludwig W. N. Schaaf, and Annette Sonntag
[PDF]

247 Delusions Associated With Quetiapine-Related Weight Redistribution. Donna A. Wirshing, Jennifer A. Boyd, Joseph M. Pierre, C. Scott Saunders, William C. Wirshing, Krist Azizian, Ketan R. Patel, Jeanne C. Ashcraft, Hasmik Darmandjian, and Jamie Feusner
[PDF]

249 Switch to Mania After Slow rTMS of the Right Prefrontal Cortex. Robin Ella, Peter Zwanzger, Robert Stampfer, Ulrich W. Preuss, Florian Muller-Siecheneder, Hans-Jurgen Moller, and Frank Padberg
[PDF]

249 Exacerbation of Idiopathic Priapism With Risperidone-Citalopram Combination. Oliver Freudenreich
[PDF]

250 Delirium Caused by Donepezil: A Case Study. Toshiro Kawashima and Shigeto Yamada
[PDF]

Book Reviews 252

NOW@Psychiatrist.com 257

Information for authors

see January 2002, pages 83-85 or our Web site at www.psychiatrist.com/author.htm